Folotyn for Non-Hodgkin's Lymphoma Frederick MD

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Jeremy Goodrich Perkins, MD
(202) 782-6751
5351 Partners Ct
Frederick, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Uniformed Services Univ Of The Hlth Sci, Bethesda Md 20814
Graduation Year: 1997

Data Provided by:
Elhamy D Eskander, MD
(301) 662-8477
501 W 7th St
Frederick, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Cairo, Fac Of Med, Cairo, Egypt (330-02 Prior 1/71)
Graduation Year: 1979

Data Provided by:
Paul Gregory Rausch, MD
(301) 662-8477
501 W 7th St Ste 1
Frederick, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Southern Ca Sch Of Med, Los Angeles Ca 90033
Graduation Year: 1970

Data Provided by:
Kanan H Hudhud
(301) 695-6777
46b Thomas Johnson Dr
Frederick, MD
Specialty
Internal Medicine, Hematology / Oncology

Data Provided by:
Kanan H Hudhu, MD
(301) 695-6777
46B Thomas Johnson Dr
Frederick, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Dr.Elhamy Eskander
(301) 662-8477
501 W 7th St # 1
Frederick, MD
Gender
M
Education
Medical School: Univ Of Cairo, Fac Of Med, Cairo
Year of Graduation: 1979
Speciality
Oncologist
General Information
Accepting New Patients: Yes
RateMD Rating
5.0, out of 5 based on 1, reviews.

Data Provided by:
Brian O'Connor
(301) 662-8477
501 W 7th St
Frederick, MD
Specialty
Hematology / Oncology

Data Provided by:
Paul Gregory Rausch
(301) 662-8477
501 W 7th St
Frederick, MD
Specialty
Hematology / Oncology

Data Provided by:
Erwood G Edwards, MD
PO Box 546
Walkersville, MD
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Eastern Va Med Sch Of The Med Coll Of Hampton Roads, Norfolk Va 23501
Graduation Year: 1982

Data Provided by:
Amr Z Hegazi
(301) 695-6777
46b Thomas Johnson Dr
Frederick, MD
Specialty
Hematology, Hematology / Oncology, Medical Oncology

Data Provided by:
Data Provided by:

Folotyn for Non-Hodgkin's Lymphoma

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com